<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4648">
  <stage>Registered</stage>
  <submitdate>3/04/2012</submitdate>
  <approvaldate>3/04/2012</approvaldate>
  <nctid>NCT01610336</nctid>
  <trial_identification>
    <studytitle>A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment</studytitle>
    <scientifictitle>A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-002569-39</secondaryid>
    <secondaryid>CINC280X2202</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - INC280

Experimental: INC280+gefitinib - INC280+gefitinib


Treatment: drugs: INC280
experimental

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phase Ib: Frequency and characteristics of dose limiting toxicities (DLTs) to the - 1 cycle= 28 days</outcome>
      <timepoint>From date of treatment until DLT, up to 52weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Phase II : Overall Response Rate of tumors per RECIST 1.1</outcome>
      <timepoint>from date of treatment until disease progression, up to 100 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS) - OS is defined as the time from the date of treatment to the date of death from any cause.</outcome>
      <timepoint>From date of treatment until death, up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency, duration, and severity of adverse events (AEs) - Safety via monitoring of AEs</outcome>
      <timepoint>30 days post study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Inhibition of c-MET signaling by pre- and post- treatment immunohistochemistry of p-c-MET, - 1 cycle= 28 days</outcome>
      <timepoint>Day 15 of cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of INC280 - 1 cycle= 28 days</outcome>
      <timepoint>Day 1 of cycle 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS) - PFS is defined as the time from the date of treatment to the date of event defined as the first documented progression per RECIST or death due to any cause.</outcome>
      <timepoint>From date of treatment to the date of disease progression, up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of gefitinib - 1 cycle= 28 days</outcome>
      <timepoint>Day 1 and 15 cycle 2, Day 1 of cycle 3 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters AUC - 1 cycle= 28 days</outcome>
      <timepoint>Day 1 and 15 cycle 2, Day 1 of cycle 3 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters Cmax - 1 cycle= 28 days</outcome>
      <timepoint>Day 1 and 15 cycle 2, Day 1 of cycle 3 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters Tmax - 1 cycle= 28 days</outcome>
      <timepoint>Day 1 and 15 cycle 2, Day 1 of cycle 3 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters accumulation ration - 1 cycle= 28 days</outcome>
      <timepoint>Day 1 and 15 cycle 2, Day 1 of cycle 3 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters half- life - 1 cycle= 28 days</outcome>
      <timepoint>Day 1 and 15 cycle 2, Day 1 of cycle 3 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>number of SAE, and severity of serious adverse events (SAEs) - Safety via monitoring SAEs</outcome>
      <timepoint>30 days post study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>number of AE - via monitoring changes in physical examination, clinical laboratory parameters, vital signs and ECGs</outcome>
      <timepoint>30 days post study treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Documented EGFR mutation

          -  Documented c-MET dysregulation

          -  Prior clinical benefit on EGFR inhibitors and then subsequent progression

             -= 18 year old

          -  Life expectancy of = 3 months

          -  ECOG performance status = 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Unable to swallow tables once or twice daily

          -  Previous treatment with c-MET inhibitor

          -  Any unresolved toxicity form previous anticancer therapy greater than grade 1

          -  History of cystic fibrosis

          -  History of acute or chronic pancreatitis

          -  Unable to undergo MRI or CT sans

          -  Known history of HIV

          -  Undergone a bone marrow or solid organ transplant

          -  Clinically significant wound or lung tumor lesions with increased likelihood of
             bleeding

          -  Pregnant or nursing

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>5/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>161</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Woolloongabba</hospital>
    <hospital>Novartis Investigative Site - Bedford Park</hospital>
    <hospital>Novartis Investigative Site - East Bentleigh</hospital>
    <hospital>Novartis Investigative Site - Auckland</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <postcode> - Auckland</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>THA</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will assess the safety and efficacy of escalating doses INC280 when added to
      gefitinib in patients with lung cancer that are known to have dysregulation of the c-MET
      pathway and who have failed after benefiting on a prior treatment with either gefitinib or
      erlotinib.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01610336</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>